Hrt Financial LP Kodiak Sciences Inc. Transaction History

Hrt Financial LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$2.29 - $4.48 $55,184 - $107,959	24,098 New	24,098 $56,000
Q4 2023 Feb 09, 2024	BUY	$1.4 - $3.24 $63,900 - $147,883	45,643 New	45,643 $138,000
Q2 2022 Aug 12, 2022	SELL	$5.04 - $9.48 $175,644 - $330,378	-34,850 Reduced 35.73%	62,690 $478,000
Q1 2022 May 16, 2022	BUY	$7.09 - $89.45 $691,558 - $8.72 Million	97,540 New	97,540 $753,000
Q3 2021 Nov 15, 2021	SELL	$81.97 - $106.94 $573,953 - $748,793	-7,002 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$77.2 - $126.54 $540,554 - $886,033	7,002 New	7,002 $651,000
Q1 2021 May 17, 2021	SELL	$110.45 - $164.47 $351,451 - $523,343	-3,182 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$60.78 - $154.03 $193,401 - $490,123	3,182 New	3,182 $467,000

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $455M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.